Morgan Stanley upgrades Charles River to Overweight
Morgan Stanley analyst Ricky Goldwasser upgraded Charles River Laboratories International, Inc. from Equal-Weight to Overweight, raising the price target to $220 from $185. The stock closed at $184.79 on Tuesday.
*this image is generated using AI for illustrative purposes only.
Morgan Stanley analyst Ricky Goldwasser upgraded Charles River Laboratories International, Inc. from Equal-Weight to Overweight, citing a revised outlook for the company. The firm also increased the price target for the stock to $220 from the previous level of $185. Charles River shares closed at $184.79 on Tuesday.
Rating and Price Target Changes
The upgrade reflects a shift in the firm's stance on Charles River's performance potential. The new price target of $220 represents a significant increase from the prior target of $185.
| Metric | Previous | New |
|---|---|---|
| Rating | Equal-Weight | Overweight |
| Price Target | $185 | $220 |
What specific factors drove Morgan Stanley to revise their outlook for Charles River Laboratories?
How might the broader biotech and pharmaceutical sectors influence Charles River's performance in the coming year?
What are the potential risks that could prevent Charles River from reaching the new $220 price target?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
